BNP Paribas Knock-Out SNW/ DE000PN203W1 /
2024-05-21 3:21:01 PM | Chg.-0.020 | Bid3:48:44 PM | Ask3:48:44 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
4.300EUR | -0.46% | 4.260 Bid Size: 18,000 |
4.270 Ask Size: 18,000 |
SANOFI SA INHABER ... | 132.2663 EUR | 2078-12-31 | Put |
GlobeNewswire
7:30 AM
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-20
Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...
GlobeNewswire
05-13
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
05-08
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
05-02
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
04-25
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance